[1]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319-323.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
　Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319-323.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
点击复制

胰高血糖素样肽-1类药物与胰腺安全性()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年05期
页码:
319-323
栏目:
胰高血糖素样肽专题
出版日期:
2015-09-20

文章信息/Info

Title:
Glucagon-like peptide-1-based therapies and pancreatic safety
作者:
赵荷珺 洪天配
300192 天津市第一中心医院内分泌科(赵荷珺); 100191 北京大学第三医院内分泌科(洪天配)
Author(s):
Zhao Hejun*;  Hong Tianpei.
*Department of Endocrinology, Tianjin First Central Hospital, Tianjin 300192, China
关键词:
胰高血糖素样肽-1;  糖尿病;  胰腺炎;  胰腺癌
Keywords:
Glucagon-like peptide-1;  Diabetes mellitus;  Pancreatitis;  Pancreatic cancer
DOI:
DOI:10.3760/cma.j.issn.1673-4157.2015.05.008
摘要:
近年来,胰高血糖素样肽-1类降糖药物的胰腺安全性引起了广泛关注,主要是因为其可能促进急性胰腺炎的发生,诱发与慢性胰腺炎相关的组织学改变,远期还可能诱发胰腺癌。流行病学研究和基础研究中存在一些相互矛盾的研究数据,其中的一些研究问题不容被忽视。因此,对现有的研究资料进行回顾和分析可为后续研究的开展和问题的阐明奠定基础。
Abstract:
There has been a debate over the pancreatic safety of glucagon-like peptide-1-based hypoglycemic therapies in recent years, especially about their potential to promote acute pancreatitis, cause histological changes related to chronic pancreatitis, and possibly, in the long run, induce pancreatic cancer. Clearly conflicting data exist between epidemiologic studies and basic studies, some of which cannot be ignored. Therefore, a full summary and analysis of these studies will lay the foundation for the future investigation.

参考文献/References:

[1] Shao Y, Yuan G, Feng Y, et al. Early liraglutide treatment is better in glucose control, beta-cell function improvement and mass preservation in db/db mice[J]. Peptides, 2014, 52: 134-142. [/br][2] Gale EA. Collateral damage: the conundrum of drug safety[J]. Diabetologia, 2009, 52(10): 1975-1982. [/br][3] Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies[J]. Gastroenterology, 2011, 141(1): 150-156. [/br][4] Labuzek K, Kozowski M, Szkudapski D, et al. Incretin-based therapies in the treatment of type 2 diabetes-more than meets the eye?[J]. Eur J Intern Med, 2013, 24(3): 207-212. [/br][5] Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use[J]. Diabetes Obes Metab, 2011, 13(6): 559-566. [/br][6] Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?[J]. Diabetes Care, 2013, 36(7): 2118-2125. [/br][7] Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study[J]. JAMA Intern Med, 2013, 173(7): 534-539. [/br][8] Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide[J]. Curr Med Res Opin, 2009, 25(4): 1019-1027. [/br][9] Funch D, Gydesen H, Tornøe K, et al. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs[J].Diabetes Obes Metab, 2014, 16(3): 273-275. [/br][10] Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials[J]. Diabetes Obes Metab, 2014, 16(1): 48-56. [/br][11] Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials[J]. Curr Med Res Opin, 2011, 27(Suppl 3): 57-64. [/br][12] Engel SS, Round E, Golm GT, et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies[J]. Diabetes Ther, 2013, 4(1): 119-145. [/br][13] Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer[J]. Diabetes Res Clin Pract, 2012, 98(2): 271-284. [/br][14] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J]. N Engl J Med, 2013, 369(14): 1317-1326. [/br][15] White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J]. N Engl J Med, 2013, 369(14): 1327-1335. [/br][16] Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting[J]. Endocr Pract, 2012, 18(4): 472-477. [/br][17] Gumbs AA. Obesity, pancreatitis, and pancreatic cancer[J]. Obes Surg, 2008, 18(9): 1183-1187. [/br][18] Butler AE, Galasso R, Matveyenko A, et al. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans[J]. Diabetologia, 2010, 53(1): 21-26. [/br][19] Ryder RE. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential(cardiovascular)benefits[J]. Diabet Med, 2013, 30(10):1148-1155. [/br][20] Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin[J]. Diabetes, 2009, 58(7): 1604-1615. [/br][21] Aston-Mourney K, Subramanian SL, Zraika S, et al. One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice[J]. Am J Physiol Endocrinol Metab, 2013, 305(4): E475-E484. [/br][22] Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D)mouse model[J]. Diabetes, 2012, 61(5): 1250-1262. [/br][23] Sipos B, Frank S, Gress T, et al. Pancreatic intraepithelial neoplasia revisited and updated[J]. Pancreatology, 2009, 9(1-2): 45-54. [/br][24] Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science, 2008, 321(5897): 1801-1806. [/br][25] Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia[J]. Gastroenterology, 2012, 142(4): 730-733.e9. [/br][26] Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors[J].Diabetes, 2013, 62(7): 2595-2604. [/br][27] Holst JJ. Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?[J]. Diabetologia, 2013, 56(9): 1869-1872. [/br][28] Williams AJ, Thrower SL, Sequeiros IM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes[J]. J Clin Endocrinol Metab, 2012, 97(11): E2109-E2113. [/br][29] Nyborg NC, Mølck AM, Madsen LW, et al. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species[J]. Diabetes, 2012, 61(5): 1243-1249. [/br][30] Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?[J]. Diabetes, 2012, 61(5): 986-988. [/br][31] Vrang N, Jelsing J, Simonsen L, et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis[J]. Am J Physiol Endocrinol Metab, 2012, 303(2): E253-E264. [/br][32] Tatarkiewicz K, Belanger P, Gu G, et al. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks[J]. Diabetes Obes Metab, 2013, 15(5): 417-426. [/br][33] Koehler JA, Baggio LL, Lamont BJ, et al. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice[J]. Diabetes, 2009, 58(9): 2148-2161. [/br][34] Butler PC, Matveyenko AV, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?[J]. Diabetologia, 2010, 53(1): 1-6. [/br][35] Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents[J]. Am J Physiol Endocrinol Metab, 2010, 299(6): E1076-E1086. [/br][36] Zhao H, Wei R, Wang L, et al. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner[J]. Am J Physiol Endocrinol Metab, 2014, 306(12): E1431-E1441. [/br][37] Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks[J]. Diabetes Care, 2013, 36(7): 2126-2132.

相似文献/References:

[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
　Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(05):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
　Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
　Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(05):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[4]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
　Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(05):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[5]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
　Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[6]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制 ——2014年美国糖尿病协会“杰出科学成就奖” 演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
　Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[7]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
　Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[8]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
　Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[9]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
　Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[10]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
　Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]

更新日期/Last Update: 2015-09-20